Particularly, results from two research groups in 2012 demonstrate that the USP22 level is increased and associated with overall survival in NSCLC patients [15], as well as patients with early-stage NSCLC [17], implying the involvement of USP22 in this specific type of cancer. This evidence concerns the gene USP22 and non-small cell lung carcinoma.